• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Ascentage Pharma Group International

    10/30/25 8:30:03 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAPG alert in real time by email
    6-K 1 ea0263035-6k_ascentage.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of October 2025

     

    Commission File Number: 001-42484

     

    ASCENTAGE PHARMA GROUP INTERNATIONAL

    (Translation of Registrant’s name into English)

     

    68 Xinqing Road

    Suzhou Industrial Park

    Suzhou, Jiangsu

    China

    (Address of principal executive offices)

      

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On October 29, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

     

     

     

     

    INDEX TO EXHIBITS

     

    Exhibit    
    Number   Exhibit Title
    99.1   Press Release dated October 29, 2025

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      ASCENTAGE PHARMA GROUP INTERNATIONAL
       
    Date: October 30, 2025 /s/ Dajun Yang
      Name: Dajun Yang
      Title: Chief Executive Officer

     

    2

     

    Get the next $AAPG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAPG

    DatePrice TargetRatingAnalyst
    3/27/2025Overweight
    Analyst
    More analyst ratings

    $AAPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Ascentage Pharma

    Analyst initiated coverage of Ascentage Pharma with a rating of Overweight

    3/27/25 8:09:51 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPG
    SEC Filings

    View All

    SEC Form 6-K filed by Ascentage Pharma Group International

    6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

    10/30/25 8:30:03 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascentage Pharma Group International

    6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

    10/7/25 9:15:24 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Ascentage Pharma Group International

    S-8 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

    9/16/25 11:38:15 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

    ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in the following investor conferences in November 2025. Goldman Sachs APAC Healthcare Corporate Day 2025: One-on-one and group investor meetings on November 5Stifel 2025 Healthcare Conference: Presentation on November 13 at 2:40 pm EST About Ascenta

    10/29/25 8:00:00 PM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025

    ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in October 2025. Piper Sandler Virtual Oncology Symposium: Fireside chat at 10:30 am EDT on October 10J.P. Morgan Global Healthcare Shanghai Conference: One-on-one and group investor meetings on October 16-172025 BofA China

    10/7/25 8:00:00 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025

    ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the following investor conferences in September 2025. Citi's 2025 Biopharma Back to School: Fireside chat at 4:00 pm EDT on September 3Cantor Global Healthcare Conference 2025: Fireside chat at 2:45 pm EDT on September 4H.C. Wainwright 27th Annual Global Inv

    8/25/25 8:00:00 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPG
    Financials

    Live finance-specific insights

    View All

    Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

    ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company's management team. Ascentage Pharma will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on Aug

    8/7/25 8:00:00 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

    ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:AAPG, HKEX: 6855)), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team. The English conference call and webcast will be he

    3/12/25 8:46:58 AM ET
    $AAPG
    Biotechnology: Pharmaceutical Preparations
    Health Care